Article
Mammary carcinoma cell derived cyclooxygenase 2 suppresses tumor immune surveillance by enhancing intratumoral immune checkpoint activity.
Breast cancer research : BCR - 1 Jan 2013
Markosyan Nune, Chen Edward P, Evans Rebecca A, Ndong Victoire, Vonderheide Robert H, Smyth Emer M
Abstract excerpt
INTRODUCTION: Systemic inhibition of the inflammatory enzyme cyclooxygenase (COX) 2 decreases the risk of breast cancer and its recurrence. However, the biology of COX-2 in the multicellular tumor microenvironment is poorly defined. METHODS: Mammary tumor onset and multiplicity were examined in ErbB2 transgenic mice that were deficient in mammary epithelial cell COX-2 (COX-2(MEC)KO) compared to wild type (WT)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.